- Home
- ELLO vs PLX Comparison
ELLO vs PLX Comparison
Compare ELLO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | PLX |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 207.1M |
| IPO Year | 1998 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ELLO | PLX |
|---|---|---|
| Price | $20.40 | $2.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0K | ★ 812.6K |
| Earning Date | 11-09-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.50 | $1.65 |
| 52 Week High | $30.34 | $3.19 |
Technical Indicators
Market Signals| Indicator | ELLO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 47.36 |
| Support Level | $20.37 | $2.21 |
| Resistance Level | $20.69 | $2.75 |
| Average True Range (ATR) | 0.64 | 0.10 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 12.62 | 38.24 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.